Axsome Therapeutics Inc. (AXSM)
Axsome Therapeutics Statistics
Share Statistics
Axsome Therapeutics has 48.77M shares outstanding. The number of shares has increased by 2.67% in one year.
| Shares Outstanding | 48.77M |
| Shares Change (YoY) | 2.67% |
| Shares Change (QoQ) | 0.63% |
| Owned by Institutions (%) | 77.24% |
| Shares Floating | 40.08M |
| Failed to Deliver (FTD) Shares | 76 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 5.75M, so 11.87% of the outstanding shares have been sold short.
| Short Interest | 5.75M |
| Short % of Shares Out | 11.87% |
| Short % of Float | 14.53% |
| Short Ratio (days to cover) | 6.08 |
Valuation Ratios
The PE ratio is -14.11 and the forward PE ratio is -68.71. Axsome Therapeutics's PEG ratio is -1.03.
| PE Ratio | -14.11 |
| Forward PE | -68.71 |
| PS Ratio | 10.51 |
| Forward PS | 2.2 |
| PB Ratio | 71.1 |
| P/FCF Ratio | -31.5 |
| PEG Ratio | -1.03 |
Enterprise Valuation
Axsome Therapeutics Inc. has an Enterprise Value (EV) of 3.42B.
| EV / Earnings | -11.89 |
| EV / Sales | 8.86 |
| EV / EBITDA | -12.17 |
| EV / EBIT | -12.17 |
| EV / FCF | -26.54 |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 3.36.
| Current Ratio | 2.11 |
| Quick Ratio | 2.04 |
| Debt / Equity | 3.36 |
| Total Debt / Capitalization | 77.06 |
| Cash Flow / Debt | -0.67 |
| Interest Coverage | -42.71 |
Financial Efficiency
Return on equity (ROE) is -5.04% and return on capital (ROIC) is -112.91%.
| Return on Equity (ROE) | -5.04% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -112.91% |
| Revenue Per Employee | $564,704.25 |
| Profits Per Employee | $-420,521.23 |
| Employee Count | 683 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.12 |
Taxes
| Income Tax | 85K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 51.62% in the last 52 weeks. The beta is 1, so Axsome Therapeutics's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | 51.62% |
| 50-Day Moving Average | 119.38 |
| 200-Day Moving Average | 96.12 |
| Relative Strength Index (RSI) | 41.81 |
| Average Volume (20 Days) | 913.8K |
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 385.69M and earned -287.22M in profits. Earnings per share was -5.99.
| Revenue | 385.69M |
| Gross Profit | 352.39M |
| Operating Income | -280.56M |
| Net Income | -287.22M |
| EBITDA | -280.56M |
| EBIT | -280.56M |
| Earnings Per Share (EPS) | -5.99 |
Balance Sheet
The company has 315.35M in cash and 191.53M in debt, giving a net cash position of 123.82M.
| Cash & Cash Equivalents | 315.35M |
| Total Debt | 191.53M |
| Net Cash | 123.82M |
| Retained Earnings | -1.12B |
| Total Assets | 568.5M |
| Working Capital | 254.96M |
Cash Flow
In the last 12 months, operating cash flow was -128.41M and capital expenditures -270K, giving a free cash flow of -128.68M.
| Operating Cash Flow | -128.41M |
| Capital Expenditures | -270K |
| Free Cash Flow | -128.68M |
| FCF Per Share | -2.69 |
Margins
Gross margin is 91.37%, with operating and profit margins of -72.74% and -74.47%.
| Gross Margin | 91.37% |
| Operating Margin | -72.74% |
| Pretax Margin | -74.45% |
| Profit Margin | -74.47% |
| EBITDA Margin | -72.74% |
| EBIT Margin | -72.74% |
| FCF Margin | -33.36% |
Dividends & Yields
AXSM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.13% |
| FCF Yield | -2.26% |
Analyst Forecast
The average price target for AXSM is $163.5, which is 40.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $163.5 |
| Price Target Difference | 40.1% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
Scores
| Altman Z-Score | 3.78 |
| Piotroski F-Score | 3 |